The combination of SPL-enforced expression with SphK1 may be a silencing strategy that decreases S1P content in the prostate, which may result in increasing the sensitivity of prostate cancer cells to anticancer therapies [18]. This evidence concerns the gene SPHK1 and Familial prostate cancer.